Quote | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Last: | $11.15 |
---|---|
Change Percent: | 0.0% |
Open: | $11.45 |
Close: | $11.15 |
High: | $11.45 |
Low: | $10.6 |
Volume: | 1,184,876 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-10 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Subject | By | Source | When |
---|---|---|---|
Right... !! is probably more like it. Absolute | biocqr | investorshub | 11/23/2020 3:40:34 PM |
Didnt mean ?? Lol. Whoops. | sgunderbarth | investorshub | 11/23/2020 2:55:38 PM |
?? | biocqr | investorshub | 11/17/2020 11:09:21 PM |
?? | sgunderbarth | investorshub | 11/17/2020 7:33:16 PM |
$1.5mil trade x $43 | sgunderbarth | investorshub | 08/12/2020 4:47:36 PM |
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
2024-03-10 12:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86). ...
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results...